Cargando…

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls

BACKGROUND: Neurofilament light chain is a marker of axonal damage and is of interest as a biofluid biomarker for PD. The objective of this study was to investigate whether CSF or serum neurofilament contributes to a combination of CSF biomarkers in defining the optimal biomarker panel for discrimin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oosterveld, Linda P., Verberk, Inge M.W., Majbour, Nour K., El‐Agnaf, Omar M., Weinstein, Henry C., Berendse, Henk W., Teunissen, Charlotte E., van de Berg, Wilma D.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027879/ https://www.ncbi.nlm.nih.gov/pubmed/31737952 http://dx.doi.org/10.1002/mds.27897

Ejemplares similares

CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson′s Disease
por: Oosterveld, Linda P., et al.
Publicado: (2020)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders
por: Herbert, Megan K., et al.
Publicado: (2015)

Serum Neurofilament light correlates with CADASIL disease severity and survival
por: Gravesteijn, Gido, et al.
Publicado: (2018)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

CSF Neurofilament Light Chain Concentrations Predict Outcome in Bacterial Meningitis
por: Chekrouni, Nora, et al.
Publicado: (2021)

High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients
por: Hakkers, Charlotte S., et al.
Publicado: (2020)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement
por: Simonini, Cecilia, et al.
Publicado: (2021)

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome
por: Khalil, M, et al.
Publicado: (2013)

Differential diagnostic performance of a panel of plasma biomarkers for different types of dementia
por: Thijssen, Elisabeth H., et al.
Publicado: (2022)

Age‐ and disease‐specific reference values for neurofilament light presented in an online interactive support interface
por: Vermunt, Lisa, et al.
Publicado: (2022)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach
por: van Dijk, Karin D., et al.
Publicado: (2010)

Is CSF neurofilament light chain measurement relevant for MS?
por: Matsui, Makoto
Publicado: (2020)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank
por: Verberk, Inge MW, et al.
Publicado: (2021)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias
por: Abu-Rumeileh, Samir, et al.
Publicado: (2018)

Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson’s Disease Patients and Is Present within Lewy Bodies
por: Chatterjee, Madhurima, et al.
Publicado: (2020)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

A rapid α‐synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy
por: Orrù, Christina D., et al.
Publicado: (2020)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

CSF neurofilament light chain reflects corticospinal tract degeneration in ALS
por: Menke, Ricarda A L, et al.
Publicado: (2015)

Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease
por: Steinacker, Petra, et al.
Publicado: (2016)

Plasma and CSF neurofilament light: Relation to longitudinal neuroimaging and cognitive measures
por: Mielke, Michelle M., et al.
Publicado: (2019)

CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression
por: Sun, Qionghua, et al.
Publicado: (2020)

Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
por: Brodovitch, Alexandre, et al.
Publicado: (2021)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Novel CSF biomarkers to discriminate FTLD and its pathological subtypes
por: del Campo, Marta, et al.
Publicado: (2018)

Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF
por: Boiten, Walter A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jque9b92i8cafua0378n77dars